Zymeworks Updates Guidance After Theravance Acquisition
Zymeworks has provided updated financial guidance following its acquisition of Theravance Biopharma. The deal adds YUPELRI (revefenacin) to Zymeworks' portfolio, which is expected to generate a consistent cash flow that will support the company's long-term growth strategy. The final transaction details were outlined by Zymeworks on Monday as part of its post-acquisition reporting. The acquisition enhances Zymeworks’ product offerings and strengthens its financial position through recurring revenue from YUPELRI, which is already approved for use.
Tickers: $TBPH
Topics: acquisition financial guidance update